Skip to main content

Month: March 2023

Sportradar Reports Fourth Quarter and Full Year 2022 Results

Full Year 2022 revenue growth of 30% exceeds annual 2022 outlookFourth quarter ROW Betting segment revenue grew 29% with Adjusted EBITDA margin of 44%Fourth quarter U.S. segment revenue grew 77%; positive Adjusted EBITDA for second consecutive quarter2023 annual outlook with growth of 24% to 26% for revenue and 25% to 33% for Adjusted EBITDA ST. GALLEN, Switzerland, March 15, 2023 (GLOBE NEWSWIRE) — Sportradar Group AG (NASDAQ: SRAD) (“Sportradar” or the “Company”), a leading global technology company focused on enabling next generation engagement in sports through providing business-to-business solutions to the global sports betting industry, today announced financial results for its fourth quarter and full year ended December 31, 2022. Full Year 2022 Highlights and Annual OutlookRevenue for the full year of 2022 increased 30%...

Continue reading

Kamada Reports Strong Fiscal Year and Fourth Quarter 2022 Financial Results, and Provides 2023 Guidance Representing Significant Profitability Growth

Total Revenues for Fiscal Year 2022 of $129.3 Million Represented Growth of 25% Compared to Fiscal Year 2021; Fourth Quarter 2022 Revenues of $45.4 Million Represented a 44% Increase Year–over–Year Fiscal Year 2022 EBITDA of $17.8 million, Represented Margins of 14%, and a 3x Increase Over Fiscal Year 2021 Recorded Highest Annual Operating Cash Flow in Kamada’s History of $28.6 Million in Fiscal Year 2022; $34.3 Million Cash Position as of December 31, 2022, Nearly Double Cash Position at Year-End 2021  Fiscal Year 2023 Revenues Expected to be in Range of $138 Million to $146 Million; 2023 EBITDA Anticipated to be in Range of $22 Million to $26 Million; Mid-Point Expected EBITDA Represents Approximately 35% Growth Year–over–Year Strong 2022 Results and 2023 Positive Outlook Driven by Multiple Growth Drivers,...

Continue reading

iTeos Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

– 10 ongoing or planned clinical trials throughout 2023 to advance both differentiated clinical programs, anti-TIGIT monoclonal antibody EOS-448/GSK4428859A and adenosine A2A receptor antagonist inupadenant – EOS-984, a first-in-class program targeting a new mechanism of action in the adenosine pathway, expected to enter clinical studies in mid-2023 – Cash and investment balance of $731.4MM as of December 31, 2022, expected to provide runway into 2026 WATERTOWN, Mass. and GOSSELIES, Belgium, March 15, 2023 (GLOBE NEWSWIRE) — iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today reported financial results for the fourth quarter and full year ended December 31, 2022. “Building...

Continue reading

Oatly Reports Fourth Quarter and Full Year 2022 Financial Results

Fiscal Year 2023 Outlook Calls for Accelerated Growth and Improved Margins Company Receives Financing Commitments of $425 Million MALMÖ, Sweden, March 15, 2023 (GLOBE NEWSWIRE) — Oatly Group AB (Nasdaq: OTLY) (“Oatly” or the “Company”), the world’s original and largest oat drink company, today announced financial results for the fourth quarter and twelve months ended December 31, 2022. Toni Petersson, Oatly’s CEO, commented, “I am proud of what the Oatly team accomplished in 2022. We took bold actions to strengthen our management team, transition our supply chain to a more asset-light model, and simplify our cost structure. We finished the year with a solid fourth quarter, and we have continued that momentum into 2023 by closing the Ya YA Foods transaction and raising $425 million in financing commitments.” Petersson continued,...

Continue reading

Eton Pharmaceuticals Announces Acquisition of Rare Disease Product Candidate ET-600

— Product is targeting rare pediatric endocrinology condition —— Potential for NDA submission in Q2 2024 — DEER PARK, Ill., March 15, 2023 (GLOBE NEWSWIRE) — Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the acquisition of rare disease product candidate ET-600 from Tulex Pharmaceuticals. ET-600 is an innovative product candidate under development for the treatment of an endocrinology condition that is estimated to impact less than 5,000 pediatric patients in the United States. “As a rare disease product that builds on our established presence in pediatric endocrinology, ET-600 is a perfect strategic fit for our portfolio,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals....

Continue reading

RVL Pharmaceuticals plc to Discuss Fourth Quarter and Full Year 2022 Financial Results and Provide Commercial Update

Conference call to be held Monday, March 20, 2023, at 8:30 a.m. ET BRIDGEWATER, N.J., March 15, 2023 (GLOBE NEWSWIRE) — RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, today announced that the Company will release its fourth quarter and full year 2022 financial results and provide a commercial update on Monday, March 20, 2023, before U.S. financial markets open. Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Mike DePetris, Principal Accounting Officer, will host a conference call as follows:Date Monday, March 20, 2023Time 8:30 a.m. ETToll free (U.S.) 800-343-4136International 203-518-9814Webcast (live and replay) ir.rvlpharma.com...

Continue reading

Kingsoft Cloud to Report Fourth Quarter and Fiscal Year 2022 Financial Results on March 29, 2023

BEIJING, March 15, 2023 (GLOBE NEWSWIRE) — Kingsoft Cloud Holdings Limited (NASDAQ: KC and HKEX: 3896) (“Kingsoft Cloud” or the “Company”), a leading independent cloud service provider in China, today announced that it will release its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2022 before the open of U.S. markets on Wednesday, March 29, 2023. Kingsoft Cloud’s management will host an earnings conference call on Wednesday, March 29, 2023 at 8:00 am, U.S. Eastern Time (8:00 pm, Beijing/Hong Kong Time on the same day). Preregistration Information Participants can register for the conference call by navigating to https://register.vevent.com/register/BI33f07c2440c0493cb833817afb236a9f. Once preregistration has been completed, participants will receive dial-in numbers, direct event passcode,...

Continue reading

Chindata Group Reports Fourth Quarter and Fiscal Year 2022 Unaudited Financial Results

BEIJING, March 15, 2023 (GLOBE NEWSWIRE) — Chindata Group Holdings Limited (“Chindata Group” or the “Company”) (Nasdaq: CD), a leading carrier-neutral hyperscale data center solution provider in Asia-Pacific emerging markets, today announced its unaudited financial results for the fourth quarter and the fiscal year of 2022 ended December 31, 2022. To supplement the Company’s consolidated financial results presented in accordance with U.S. GAAP, Chindata Group uses adjusted EBITDA, adjusted EBITDA margin, adjusted net income and adjusted net income margin as non-GAAP financial measures, which are described further below. Recent Financial and Operating HighlightsRealizing ten straight quarters of consensus beat and 2022 full year guidance upbeat, 2023 full year guidance implies 30% growth in revenue. Revenue and adjusted EBITDA...

Continue reading

Calibre Delivers High-Grade Ore From the Pavon Central Mine Ahead of Schedule to the Libertad Mill Averaging 1,000 Tonnes Per Day at 7.39 g/t Gold in February

VANCOUVER, British Columbia, March 15, 2023 (GLOBE NEWSWIRE) — Calibre Mining Corp. (TSX: CXB; OTCQX: CXBMF) (“Calibre” or the “Company”) is pleased to announce that mining at its Pavon Central open pit mine operation commenced in January, ahead of budget, and averaged 1,000 tonnes per day to the Libertad Mill in February. Darren Hall, President and Chief Executive Officer of Calibre, stated: “I am very pleased with the team’s efforts to safely deliver the Pavon Central mine ahead of schedule and on budget. Pavon Central marks another significant milestone as we leverage the surplus processing capacity at the Libertad mill. With 1,000 tonnes per day averaging in excess of 7g/t delivered to Libertad in February, Pavon Central will be a significant contributor to our grade driven production growth during 2023 and beyond.” ON BEHALF...

Continue reading

Chicago Atlantic Real Estate Finance Declares Common Stock Dividend of $0.47 for the First Quarter of 2023

CHICAGO, March 15, 2023 (GLOBE NEWSWIRE) — Chicago Atlantic Real Estate Finance, Inc. (NASDAQ: REFI) (“Chicago Atlantic” or the “Company”), a commercial mortgage real estate investment trust, announced that its board of directors has declared a regular quarterly cash dividend of $0.47 per share for the first quarter of 2023. The dividend, which equates to an annualized rate of $1.88 per common share, is payable on April 14, 2023, to shareholders of record as of the close of business on March 31, 2023. In light of the recent news regarding Silicon Valley Bank and Signature Bank New York, the Chicago Atlantic team has assessed the portfolio companies it invests in and has found that they have no exposure to Silicon Valley Bank, Signature Bank New York or First Republic Bank. About Chicago Atlantic Real Estate Finance,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.